Current options for fecal transplantation in clostridium difficile infection

Nathaniel Aviv Cohen, Nitsan Maharshak

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

Abstract

Clostridium difficile infection is the most common cause of hospital acquired diarrhea and carries significant morbidity and mortality. Current treatment options are limited by high rates of recurrence, and fecal transplantation has proven to be an effective and safe option, with very low rates of recurrence. Multiple mechanisms contribute to the success of this treatment, including prevention of colonization through altering bile salt metabolism and nutrient limitation, antiinflammatory effects, producing bactericidal proteins, and possibly promoting epithelial integrity. This success has lead to increased research in the field of stool-based therapies, which promises greater accessibility, acceptability, and safety than current treatments.

Original languageEnglish
Title of host publicationMicrobiome and Metabolome in Diagnosis, Therapy, and other Strategic Applications
PublisherElsevier
Pages177-184
Number of pages8
ISBN (Electronic)9780128152492
ISBN (Print)9780128152508
DOIs
StatePublished - 1 Jan 2019

Keywords

  • Antibiotics
  • Diarrhea
  • Fecal microbial transplantation
  • Gastrointestinal infections
  • Microbiome
  • Microbiota
  • Mucosal immunology

Fingerprint

Dive into the research topics of 'Current options for fecal transplantation in clostridium difficile infection'. Together they form a unique fingerprint.

Cite this